| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8cb6a648f90ce7609de5ca286e7ef9ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2828cc7688b838e3cf7022b5f07d4c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa468bc2f808360ce28ef184674694f7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-23 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-01001 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-50 |
| filingDate |
2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_588b7a2a1b4de6825d98cc83e80280d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e102028e9c43a7e44f3a0365661fd727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dc7b26d082a0a3f99aa63ed1f718651 |
| publicationDate |
2012-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012075173-A2 |
| titleOfInvention |
Compositions and method for deimmunization of proteins |
| abstract |
The invention provides deimmunized mutant proteins having reduced immunogenicity while exhibiting substantially the same or greater biological activity as the proteins of interst from which they are derived, as exemplified by mutant L-asparaginase that comprises amino acid substitutions compared to wild type L-asparaginase. The invention further provides methods for screening mutant deimmunized proteins that have substantially the same or greater biological activity as a protein of interest, and methods for reducing immunogenicity, without substantially reducing biological activity, of a protein of interest. The invention's compositions and methods are useful in, for example, therapeutic applications by minimizing adverse immune responses by the host mammalian subjects to the protein of interest. Thus, the invention further provides methods for treating disease comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising at least one of the mutant deimmunized proteins produced by the invention's methods. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111050784-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022087589-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111117987-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019032952-A1 |
| priorityDate |
2010-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |